A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission
Phase 2
Not yet recruiting
- Conditions
- Extra-nodal Involvement, Large MassAdvanced Diffuse Large B-Cell LymphomaRadiotherapy
- Interventions
- Drug: 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapyRadiation: Radiotherapy beyond standard R-CHOP Chemotherapy
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-05-25
- Target Recruit Count
- 108
- Registration Number
- NCT05874778
H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
Phase 2
Not yet recruiting
- Conditions
- Primary Hepatocellular CarcinomaPortal Vein Thrombosis
- Interventions
- Drug: Recombinant human adenovirus type 5 + TACE
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-24
- Target Recruit Count
- 38
- Registration Number
- NCT05872841
A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer
Phase 3
Recruiting
- Conditions
- HER-2 Positive Breast Cancer
- Interventions
- Drug: TCbHP VS ddEC-THP
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-05-23
- Target Recruit Count
- 832
- Registration Number
- NCT05871918
- Locations
- 🇨🇳
Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Unrescetable Hepatocellular Carcinoma
- Interventions
- Drug: HAIC+Durvalumab+Tremelimumab+Bevacizumab
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-08-23
- Target Recruit Count
- 30
- Registration Number
- NCT05864755
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
Phase 1
Recruiting
- Conditions
- Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2024-04-15
- Target Recruit Count
- 30
- Registration Number
- NCT05856864
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous Carcinoma
Recruiting
- Conditions
- Squamous Cell CarcinomaLung NeoplasmExosomes
- Interventions
- Diagnostic Test: collect plasma samples and clinical features
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2023-05-11
- Target Recruit Count
- 60
- Registration Number
- NCT05854030
- Locations
- 🇨🇳
TianjinCIH, Tianjin, Tianjin, China
Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer
Phase 2
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-05-10
- Target Recruit Count
- 30
- Registration Number
- NCT05853172
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)
Phase 2
Not yet recruiting
- Conditions
- Non Small Cell Lung Cancer Recurrent
- Interventions
- Drug: Toripalimab, Anlotinib and Chemotherapy
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Target Recruit Count
- 30
- Registration Number
- NCT05842018
A Multicenter, Cross-sectional Study on the Quality of Life in Long-term Survival Esophageal Cancer Patients After Radical Radiochemotherapy/Radiotherapy
Not yet recruiting
- Conditions
- Assessing the Current Quality of Life Status of Esophageal Cancer Patients Who Have Undergone Radical Chemoradiotherapy/Radiotherapy and Long-term Survival
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-07-07
- Target Recruit Count
- 1000
- Registration Number
- NCT05828875
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Unrescetable Hepatocellular Carcinoma
- Interventions
- Drug: HAIC+Cadonilimab+Bevacizumab
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-04-20
- Target Recruit Count
- 30
- Registration Number
- NCT05821361
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
© Copyright 2025. All Rights Reserved by MedPath